Login to Your Account



Halozyme In Potential $612M Deal For Enhanze With Roche

By Karen Pihl-Carey


Thursday, December 7, 2006
Halozyme Therapeutics Inc.'s stock surged 59.2 percent Wednesday following news of an Enhanze technology licensing deal with F. Hoffmann-La Roche Ltd. worth up to $612 million plus royalties. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription